Search Results - "Deacon, C F"

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas by Deacon, C. F., Lebovitz, H. E.

“…Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent does not generally provide durable glycaemic control over the long…”
Get full text

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down by Nauck, M. A, Vardarli, I, Deacon, C. F, Holst, J. J, Meier, J. J

“…The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting…”
Get full text

Circulation and degradation of GIP and GLP-1 by Deacon, C F

“…The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from the intestinal K- and L-cells,…”
Get more information

An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future by Madsbad, S., Kielgast, U., Asmar, M., Deacon, C. F., Torekov, S. S., Holst, J. J.

“…Incretin‐based therapies, such as the injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists and orally administered dipeptidyl peptidase‐4 (DPP‐4)…”
Get full text

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes by Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., Foley, J. E.

“…Aims/Hypothesis: The dipeptidyl peptidase IV inhibitor, vildagliptin, increases levels of intact glucagon-like peptide-1 (GLP-1) and improves glycemic control…”
Get full text

Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies by Bak, M. J., Wewer Albrechtsen, N. J., Pedersen, J., Knop, F. K., Vilsbøll, T., Jørgensen, N. B., Hartmann, B., Deacon, C. F., Dragsted, L. O., Holst, J. J.

“…Aims To evaluate the performances of commercially available glucagon‐like peptide‐1 (GLP‐1) assays and the implications for clinical studies. Methods Known…”
Get full text

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs by Hjøllund, K. R., Deacon, C. F., Holst, J. J.

Get full text

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors by Holst, J J, Deacon, C F

Get full text

Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors by Aaboe, K., Akram, S., Deacon, C. F., Holst, J. J., Madsbad, S., Krarup, T.

“…Aims To examine whether 12 weeks of treatment with a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, sitagliptin, influences the insulin secretion induced by…”
Get full text

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs by Simonsen, L, Holst, J. J, Deacon, C. F

“…Aims/hypothesis The insulinotropic hormone, glucagon-like peptide-1 (GLP-1), is rapidly degraded in vivo as a result of the combination of extensive enzymatic…”
Get full text

Ghrelin secretion in humans – a role for the vagus nerve? by Veedfald, S., Plamboeck, A., Hartmann, B., Vilsbøll, T., Knop, F. K., Deacon, C. F., Svendsen, L. B., Holst, J. J.

“…Background Ghrelin, an orexigenic peptide, is secreted from endocrine cells in the gastric mucosa. Circulating levels rise in the preprandial phase, suggesting…”
Get full text

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig by PLAMBOECK, A, HOIST, J. J, CARR, R. D, DEACON, C. F

“…The incretin hormone glucagon-like peptide 1 (GLP-1) has antihyperglycaemic effects, but its therapeutic usefulness is limited by its metabolic instability…”
Get full text

GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice by Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., Calcutt, N. A.

“…Aim: Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone that induces glucose‐dependent insulin secretion and may have neurotrophic properties. Our aim was…”
Get full text

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide by DEACON, Carolyn F, NAUCK, Michael A, MEIER, Juris, HÜCKING, Katrin, HOLST, Jens Juul

“…Gastric inhibitory polypeptide (GIP) is susceptible to degradation, but only recently has dipeptidyl peptidase IV been identified as the enzyme responsible…”
Get full text

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review by Deacon, C.F

“…The dipeptidyl peptidase (DPP)-4 inhibitors are a new class of antihyperglycaemic agents which were developed for the treatment of type 2 diabetes by rational…”
Get full text

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes by HOLST, J. J, DEACON, C. F

“…Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. J J Holst and C F Deacon Department of Medical Physiology, University…”
Get full text

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects by Rhee, N A, Østoft, S H, Holst, J J, Deacon, C F, Vilsbøll, T, Knop, F K

“…ObjectiveInhibition of dipeptidyl peptidase 4 (DPP4) is thought to intensify the physiological effects of the incretin hormones. We investigated the effects of…”
Get full text

The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study by Stevens, J. E., Horowitz, M., Deacon, C. F., Nauck, M., Rayner, C. K., Jones, K. L.

“…Summary Background The rate of gastric emptying (GE) and subsequent release of the incretin hormones, glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent…”
Get full text

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs by Deacon, CF, Wamberg, S, Bie, P, Hughes, TE, Holst, JJ

“…The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are degraded by dipeptidyl peptidase IV (DPP IV),…”
Get full text

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects by MEIER, J. J, DEACON, C. F, SCHMIDT, W. E, HOIST, J. J, NAUCK, M. A

“…The incretin effect describes the augmentation of postprandial insulin secretion by gut hormones. It is not known whether glucagon secretion is also influenced…”
Get full text